BioCentury
ARTICLE | Clinical News

Roxadustat: Phase IIa data

August 24, 2015 7:00 AM UTC

A U.S. Phase IIa trial in 96 evaluable patients with anemia related to stage 3/4 CKD who are not receiving dialysis showed that 0.7, 1, 1.5 and 2 mg/kg roxadustat given twice weekly or thrice weekly f...